Development of Clinical and Biological Database
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
About this trial
The BCB is a tool:
* for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials; * to help scientists understand and explain phenomena ranging from the interaction of molecules to the whole metabolism of the organism in normal and pathological situations; * to identify potential strategies for prevention, diagnosis, management and analysis of cancer subtypes.
The creation of a broad clinical and biological prospective base dedicated to different types of cancer is essential for the development of such projects.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age> at 18 years old,
Patient with invasive or in situ tumor pathology (proven or suspected) any stage confounded,
Patient in ICM at diagnosis
a digestive cancer (esophagus, stomach, pancreas, colon, rectum, anal canal) or
Disqualifiers
Patient not affiliated to a social protection scheme,
Patient whose regular follow-up is a priori impossible for psychological, familial, social or geographical reasons,
Pregnant and / or nursing women,
Subject under tutelage, curatorship or safeguard of justice,
Trial design
Design model
Single group
Treatments tested in this trial
biological collection
Biological/Vaccine* Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. * Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.
Treatment groups
4,000 Participants
are divided into 1 treatment groupGroup A: Biological collectionExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Proportion of patients who consent to participate in the study
the proportion of patients who consent to participate in the study among the screened patients
Time frame
through study completion, an average of 1 yearOther outcomes
1
Quality of life assessment at baseline for all participants in the study
Questionnaire assessment to measure the quality of life at baseline
Time frame
through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov